Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol

BACKGROUND: Certolizumab pegol is used to treat ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis. Unlike other monoclonal antibodies such as infliximab and adalimumab, certolizumab does not contain an Fc fraction and hence does not induce complement activation....

Descripción completa

Detalles Bibliográficos
Autores principales: Baysal, Mehmet, Ümit, Elif Gülsüm, Sarıtaş, Fatih, Kodal, Nil Su, Demir, Ahmet Muzaffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158467/
https://www.ncbi.nlm.nih.gov/pubmed/29687787
http://dx.doi.org/10.4274/balkanmedj.2017.1224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158467/
https://www.ncbi.nlm.nih.gov/pubmed/29687787
http://dx.doi.org/10.4274/balkanmedj.2017.1224

Ejemplares similares